Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tarumoto, T.
Right arrow Articles by Ozawa, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tarumoto, T.
Right arrow Articles by Ozawa, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 30:159-162 (2000)
© 2000 Foundation for Promotion of Cancer Research

A Case of Bilateral Heel Ulcers Associated with Hydroxyurea Therapy for Chronic Myelogenous Leukemia

Takahisa Tarumoto1, Shigehiko Imagawa1, Taketo Hotta2, Ken Ohmine1, Tadashi Nagai1, Masaaki Takatoku1, Norio Komatsu1, Kiyohiko Hatake1 and Keiya Ozawa1,+

Departments of 1Hematology and 2Dermatology, Jichi Medical School, Tochigi, Japan

Bilateral heel skin ulcers developed in a 50-year-old male in the chronic phase of chronic myelogenous leukemia who had been receiving hydroxyurea (HU) therapy for 3 years. Histological examination showed perivascular lymphocytic inflammation without vasculitis. After interruption of HU administration, the heel ulcers were completely resolved within 2 months. The clin­ical course strongly suggested that the heel ulcers were induced by long-term HU therapy.

+ For reprints and all correspondence: Shigehiko Imagawa, Department of Hematology, Jichi Medical School, Minamikawachi-machi, Tochigi 329-0498, Japan. E-mail: simagawa@jichi.ac.jpAbbreviations: HU, hydroxyurea; CML, chronic myelogenous leukemia; IFN, interferon; Ph, Philadelphia chromosome; PGE1, prostaglandin E1 (alprostadil)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
R. M. Stone
Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach
Oncologist, June 1, 2004; 9(3): 259 - 270.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.